Previous 10 | Next 10 |
home / stock / azncf / azncf news
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...
2023-08-11 17:59:00 ET Summary Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products ...
2023-08-10 11:01:31 ET Summary Organon & Co. posted its Q2 2023 earnings on 8th August. The Merck spinouts' 3 main divisions are Women's Health, Biosimilars, and Established Brands. Total revenues were $1.6bn - up 4% ex-FX fluctuations - and diluted EPS was $0.95 - both ou...
2023-08-08 12:46:53 ET Summary China's economic recovery has turned out to be slower than expected, with growth forecasts reduced for 2023. But strong domestic consumption indicates that there are still pockets of recovery. Segments like jewelry, apparel, and medicines are doing w...
2023-08-08 12:10:19 ET AstraZeneca ( OTCPK:AZNCF ) had declared $0.93/share semi-annual dividend. Payable Sept. 11; for shareholders of record Aug. 11; ex-div Aug. 9. See AZNCF Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Astra...
2023-08-07 17:44:22 ET Summary On July 20, Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. However, those results were overshadowed by a federal judge's decision to dismiss a JNJ subsidiary's bankruptcy fili...
2023-07-30 05:55:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund outperformed its benchmark index and the all-cap growt...
2023-07-30 01:20:34 ET Summary AstraZeneca's revenue for the second quarter of 2023 was $11.42 billion, up 5% from the previous quarter and 6% from the second quarter of 2022. At the end of June 2023, AstraZeneca's total debt was about $30.8 billion, down $1.68 billion from the pr...
2023-07-29 10:03:55 ET Summary AstraZeneca's H1 2023 results show robust growth, with revenues ex-COVID-19 medicines increasing by 16% YoY, core EPS by 21%, and gross profit margin of 82%. Oncology and rare disease segments drove growth, with treatments like Tagrisso, Farxiga, and...
News, Short Squeeze, Breakout and More Instantly...
Inaugural Asia Summit on Global Health successfully explores healthcare landscape HONG KONG, Nov 25, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural...
Inaugural Asia Summit on Global Health opens today HONG KONG, Nov 24, 2021 - (ACN Newswire) - Co-organised by the Government of the Hong Kong Special Administrative Region (HKSAR) and the Hong Kong Trade Development Council (HKTDC), the inaugural Asia Summit on Global Health (...
A new study with information regarding the “rare but devastating” blood clotting issue affiliated with the Oxford- AstraZeneca (OTCMKTS: AZNCF) Covid-19 vaccine has been released. Nevertheless, according to British scientists, there have been no new cases of blood cl...